Towards a universal influenza vaccine: Volunteer virus challenge studies in quarantine to speed the development and subsequent licensing

British Journal of Clinical Pharmacology

Volumn 76, Issue 2, 2013, Pages 210-216

  Oxford, John S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Haemagglutinin; Human volunteers; Influenza; Matrix; Quarantine; Universal vaccine

Indexed keywords

ANTIBODY; CD4 ANTIGEN; INFLUENZA VACCINE; M PROTEIN; M2E PROTEIN; MEMBRANE PROTEIN; NP PROTEIN; PROTEIN M1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CROSS REACTION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNITY; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A; LICENSING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VACCINIA VIRUS;

HAEMAGGLUTININ; HUMAN VOLUNTEERS; INFLUENZA; MATRIX; QUARANTINE; UNIVERSAL VACCINE;

DRUG APPROVAL; HUMANS; IMMUNITY; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; QUARANTINE; RESEARCH SUBJECTS; TIME FACTORS; VACCINATION;

EID: 84880673810     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12146     Document Type: Article

References (47)

1. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines? Philos Trans R Soc 2011; 366: 2766-2773.
2. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011; 42: 1-8.
3. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes 2010; 12: 280-286.
4. Oxford JS, Gilbert A, Lambkin-Williams R. Influenza vaccines: a short but illustrious history of dedicated science enabling the rapid global production of A/Swine (H1N1) vaccine in the current pandemic. In: Influenza Vaccines For the Future, 2nd edn. eds Rappuoli R, Del Giudice G Basel: Birkhäuser Verlag, 2011; 115-147.
5. Virelizier JI, Posthethwaite R, Schild GC, Allison AC. Antibody responses to antigenic determinants of influenza virus haemagglutinin. J Exp Med 1974; 140: 1559-1570.
6. Black S, Nicolay U, Vesikari T, Knuf MD, Giudice G, Cioppa GC, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis 2011; 12: 1081-1085.
7. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety and immunogenicity of a Vero-cell culture derived trivalent influenza vaccine: a multicentre, double-blind, randomised placebo-controlled trial. Lancet 2011; 377: 751-759.
8. Hobson D, Curry RL, Beare AS, Gardner AW. The role of serum haemagglutination inhibiting antibody in protection against challenge infection with influenza A and B viruses. J Hyg 1972; 70: 767-777.
9. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008; 453: 615-619.
10. Davies J. Swine flu vaccines reaching the finish line. Cell 2009; 139: 449-451.
11. Darwood FS, Iuliano D, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks A, Buch P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang S, Katz MA, Krishnan A, Lal R, Montgomery JM, Mølbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson M. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A (H1N1) virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687-695.
12. Werner GH. Immunite croissée heterotypique chez la souris entre virus grippaux humans de types A and A2. C.R. Acad. Sci 1966; 264: 1913-1916.
13. Schulman JL, Kilbourne ED. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 1966; 89: 170-174.
14. Keijtz JH, Bodewes R, Van den Brand JM, De Mutsert G, Bass C, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009; 27: 4983-4989.
15. Laver WR. Isolation of haemagglutinin sub units from influenza viruses. J Mol Biol 1964; 9: 109-112.
16. Oxford JS, Schild GC. Immunological and physicochemical studies of influenza matrix (M) polypeptides. Virology 1976; 74: 394-402.
17. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64: 1375-1377.
18. Collier L, Kellam P, Oxford JS. Human Virology: A Text for Students of Medicine. Oxford: Oxford University Press, 2011.
19. Belshe RB, Mendelman PM. Safety and efficacy of live attenuated, cold adapted influenza vaccine. Immunol Allergy Clin North Am 2003; 23: 745-767.
20. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006; 3: 102-115.
21. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou VM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5: 1157-1163.
22. Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. M2e-based universal influenza A vaccine. Vaccine 2009; 27: 6280-6283.
23. Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MHZ. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology 2012; 430: 63-72.
24. Stoloff GA, Caparros-Wanderley W. Synthetic multi epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007; 37: 2441-2449.
25. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29: 5145-5152.
26. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, Jennings GT, Saudan P, Pumpens P, Bachmann MF. Versatile VLP carrier for epitope based vaccines. PLoS ONE 2010; 5: 31e. 9809.
27. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN. Immunopotentation of trivalent influenza vaccine when given with VAX 102 a recombinant influenza M2e vaccine fused to the TLRS ligand flagellin. PLoS ONE 2010; 5: e14442.
28. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T. A universal epitope based influenza vaccine and its efficacy against H5N1. Vaccine 2009; 27: 2099-2107.
29. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG. Comparative immunogenicity evaluations of influenza A virus M2 peptides as recombinant virus like particle and conjugate vaccines in mice and monkeys. Vaccine 2009; 27: 1440-1447.
30. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012; 55: 19-25.
31. Bommakanti G, Citron M, Hepler RW, Callhan C, Heidecker GL, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, Meulen J, Liang X, Varadarajan R. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010; 107: 13701-13706.
32. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. Influenza virus vaccine based on the conserved haemagglutinin stalk domain. M Bio. 2010; 1: 1-9.
33. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. PNAS 2012; 109: 2573-2578.
34. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. Vaccination with a systemic peptide from the influenza virus haemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010; 107: 18979-18984.
35. Babon JAB, Cruz J, Ennis FA, Yin L, Tarajima M. A human CD4 cell epitope in the influenza haemagglutinin is cross-reactive to influenza A subtypes and to influenza B virus. J Virol 2012; 86: 9233-9243.
36. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralising epitope conserved between the haemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67: 2552-2558.
37. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakani A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Structural and functional bases for broad-spectrum neutralisation of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16: 265-273.
38. Wood JM, Schild GC. Newman RW, Seagroatt V. An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccine. J Biol Stand 1977; 5: 237-247.
39. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. Pre existing influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 28: 274-280.
40. Oxford JS, Gelder C, Lambkin R. Would you volunteer to be quarantined and infected with influenza virus? Expert Rev Anticancer Ther 2005; 3: 1-2.
41. Oxford JS, Oxford JR. Clinical, scientific and ethnology studies of influenza vaccines and antivirals in quarantine. Expert Rev Vaccines 2012; 11: 1-9.
42. Beare AS, Read SE. The study of antiviral compounds in volunteers. In: Chemoprophylaxis and Virus Infections, Vol. 2, ed. Oxford JS Cleveland, OH: CRC Press, 1977; 27-55.
43. McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 1981; 43: 276-284.
44. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. Lancet Infect Dis 2012; 12: 696-702.
45. Zaman M, Ashraf S. Dreyer NA, Toovey S. Human infection with avian influenza virus, Pakistan, 2007. Emerg Infect Dis 2011; 17: 1056-1059.
46. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 NA/H1N1 virus is ferrets. Nature 2012; 486: 420-428.
47. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012; 337: 1534-1541.